REG - Scancell Holdings - Notice of Results

Scancell HoldingsAnnouncement

04/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250904:nRSD9201Xa&default-theme=true

RNS Number : 9201X  Scancell Holdings Plc  04 September 2025

4 September 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Notice of Final Results and Investor Presentation

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and
Moditope® active immunotherapies to treat cancer, will announce its audited
results for the year ended 30 April 2025 and provide a business update on
progress achieved post-period end on Thursday 11 September 2025.

Phillip L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief
Financial Officer, will host a live webcast and Q&A session for analysts
and investors on the day of the results at 13:00 BST.

 

If you would like to join the webcast, please follow this link:

 

Scancell Holdings PLC Full Year Results | SparkLive | LSEG
(https://sparklive.lseg.com/ScancellHoldings/events/a41b0c94-5a49-41ef-b46e-aff660528730/scancell-holdings-plc-full-year-results)

 

 For further information, please contact:
 Scancell Holdings plc                                         +44 (0) 20 3709 5700
 Phillip L'Huillier, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)  +44 (0) 20 7886 2500
 Emma Earl/ Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                +44 (0) 20 3705 9330
 David Wilson, Claes Spang

 Investor and media relations
 Mary-Ann Chang                                                +44 (0) 20 7483 284853

                                                               MaryAnnChang@scancell.co.uk

Scancell (LSE:SCLP; www.scancell.co.uk (http://www.scancell.co.uk) ) is a
clinical stage company leveraging two proprietary platforms, Immunobody® and
Moditope®, to develop targeted off-the-shelf, patient-accessible active
immunotherapies designed to generate safe, potent and long-lasting
tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+,
an Immunobody® active immunotherapy that has demonstrated  monotherapy
activity in adjuvant melanoma. When combined with checkpoint therapies it
showed additional clinical benefit over the checkpoints (CPI) alone in the
ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient
population that iSCIB1+, in combination with CPIs bring benefit has been
identified - enabling a precision-biomarker led registrational development.
The lead Moditope® peptide active immunotherapy, Modi-1, is being
investigated in a Phase 2 study in a broad range of solid tumours and also has
shown encouraging interim clinical data. Scancell's wholly-owned subsidiary,
Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of
high affinity GlyMab® antibodies targeting tumour specific glycans, two of
which already have been licensed and are being developed by Genmab A/S, an
international biotechnology company and global leader in the antibody
therapeutics space.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFLFVRADIVIIE